Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Pelcitoclax · APG-1252

Small molecule · Inhibitor of B-cell lymphoma 2 (BCL2) and Bcl-XL (BCL2L1) · developed by Ascentage Pharma Group

Phase 1/2 Most advanced trial (none active)
AAPG Developer
2 Registered trials

What is Pelcitoclax?

Pelcitoclax is a BH3 mimetic and selective inhibitor of the anti-apoptotic proteins Bcl-2 and Bcl-XL. It binds to and inhibits these pro-survival proteins, restoring apoptotic processes in Bcl-2/Bcl-XL-dependent tumor cells. It is studied in relapsed/refractory non-Hodgkin lymphoma and acute lymphoblastic leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
APG-1252
Drug type
Small molecule
Targets
B-cell lymphoma 2 (BCL2), Bcl-XL (BCL2L1)
Mechanism
Inhibitor of B-cell lymphoma 2 (BCL2) and Bcl-XL (BCL2L1)
Pathways
apoptosis
Therapy area
Oncology
Developer
Ascentage Pharma Group Inc. (AAPG)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
317UBD60ML

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05186012 Phase 1/2 NHL, Adult Unknown AAPG
NCT07428486 Phase 1 Phase I Withdrawn AAPG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

FLAG ChemotherapyLisaftoclaxLymphoblastic Leukemia AcuteNHL, AdultPelcitoclaxPhase IRelapsed/Refractory

Other drugs acting on BCL2 / BCL2L1

Venetoclax FDA approved AZD5991 Phase 2/3 Lisaftoclax Phase 3

More from Ascentage Pharma Group

Alrizomadlin Phase 1/2 APG-2449 Phase 1 APG-3288 Phase 1 APG-5918 Phase 1 Dasminapant Phase 1/2 Lisaftoclax Phase 3 Olverembatinib Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AAPG page.

Follow AAPG, the company behind Pelcitoclax

See AAPG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AAPG catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.